Sandbox Reserved 1107: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
=Crystal structure of MraY bound to carbacaprazamycin, 6OYH = | |||
<StructureSection load='6OYH' size='340' side='right' caption='Crystal structure of two MraY dimers'> | <StructureSection load='6OYH' size='340' side='right' caption='Crystal structure of two MraY dimers'> | ||
| Line 10: | Line 12: | ||
<scene name='42/421575/Carbacaprazamycin/1'>Carbacaprazamycin</scene> is a chemically stable analog of caprazamycin nucleoside inhibitors <ref name="more1">DOI:10.1021/id5000376</ref>. One particular characteristic of caprazamycin nucleoside inhibitors is that they have uridine on their structure. It has been shown that Mray inhibitors contains a uridine moiety. | <scene name='42/421575/Carbacaprazamycin/1'>Carbacaprazamycin</scene> is a chemically stable analog of caprazamycin nucleoside inhibitors <ref name="more1">DOI:10.1021/id5000376</ref>. One particular characteristic of caprazamycin nucleoside inhibitors is that they have uridine on their structure. It has been shown that Mray inhibitors contains a uridine moiety. | ||
== Relevance == | == Relevance == | ||
Drug resistant bacteria are the cause of death of millions of people worldwide. In the USA alone, hospital infections associated with antibiotic-resistant pathogens cause 99 000 deaths per year<ref name="more2">PMID:30349322</ref>. The development of new antibiotics with new mechanism of action is urgent. Structural analysis of the binding of carbacaprazamycin to MraY provides a better understanding of the chemical logic of MraY inhibition, which can help in the development of novel approaches for the design of antibiotics targeting MraY. | Drug resistant bacteria are the cause of death of millions of people worldwide. In the USA alone, hospital infections associated with antibiotic-resistant pathogens cause 99 000 deaths per year<ref name="more2">PMID:30349322</ref>. The development of new antibiotics with new mechanism of action is urgent. Structural analysis of the binding of carbacaprazamycin to MraY provides a better understanding of the chemical logic of MraY inhibition, which can help in the development of novel approaches for the design of antibiotics targeting MraY. | ||
= Function = | = Function = | ||
| Line 27: | Line 23: | ||
= Structure = | = Structure = | ||
<scene name='42/421575/Mray/1'>MraY</scene> is a ''' dimeric membrane-bound enzyme''', for which the N and the C termini are located on the periplasmic side. This protein is made of four extracellular loops, five cytoplasmic loops (named A,B … and E) and ten transmembrane helices named TM1 to TM10. Though, TM9 is cleaved by a glycin residue into two helical segments named TM9a and TM9b. Furthermore, there is an additional helix between TM9b and TM10, which is only 11 residues long and is called TM9c. TM9c contains a <scene name='42/421575/His_triad/1'>HHH motif</scene> (H324,325 and 326) which plays a role in the enzyme’s substrat selectivity and is a part of the catalytic site <ref name="one">PMID:29778697</ref>. For example; they interact with tunicamycin and <scene name='42/421575/Mray_in_complex_with_md2/1'>MD2</scene>. This small loop binds two Ni2+ ions, one on the two first histidines and the other one on the last one. Another part of this site is the residues corresponding to <scene name='42/421575/Asp117_and_asp118_which_are/1'>Asp117 and Asp118 which are involved in Mg2+coordination</scene> <ref name="four">PMID:29438582</ref>.TM5–TM10 and loops C and D also play a role in the catalytic site and contain many polar and charged amino acids residues <ref name="one">PMID:29778697</ref>. Also, some polar and charged amino acids on TM9b and loop E are pointing toward the active site, making it even more hydrophilic <ref name="four">PMID:29438582</ref>. | <scene name='42/421575/Mray/1'>MraY</scene> is a ''' dimeric membrane-bound enzyme''', for which the N and the C termini are located on the periplasmic side. This protein is made of four extracellular loops, five cytoplasmic loops (named A,B … and E) and ten transmembrane helices named TM1 to TM10. Though, TM9 is cleaved by a glycin residue into two helical segments named TM9a and TM9b. Furthermore, there is an additional helix between TM9b and TM10, which is only 11 residues long and is called TM9c. TM9c contains a <scene name='42/421575/His_triad/1'>HHH motif</scene> (H324,325 and 326) which plays a role in the enzyme’s substrat selectivity and is a part of the catalytic site <ref name="one">PMID:29778697</ref>. For example; they interact with tunicamycin and <scene name='42/421575/Mray_in_complex_with_md2/1'>MD2</scene>. This small loop binds two Ni2+ ions, one on the two first histidines and the other one on the last one. Another part of this site is the residues corresponding to <scene name='42/421575/Asp117_and_asp118_which_are/1'>Asp117 and Asp118 which are involved in Mg2+coordination</scene> <ref name="four">PMID:29438582</ref>.TM5–TM10 and loops C and D also play a role in the catalytic site and contain many polar and charged amino acids residues <ref name="one">PMID:29778697</ref>. Also, some polar and charged amino acids on TM9b and loop E are pointing toward the active site, making it even more hydrophilic <ref name="four">PMID:29438582</ref>. | ||
Revision as of 01:39, 17 January 2020
Crystal structure of MraY bound to carbacaprazamycin, 6OYH
| ||||||||||||